Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $662000.0.

  • Artiva Biotherapeutics' Depreciation & Amortization (CF) rose 558.21% to $662000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 555.79%. This contributed to the annual value of $2.4 million for FY2024, which is 728.16% up from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Depreciation & Amortization (CF) of $662000.0 as of Q3 2025, which was up 558.21% from $641000.0 recorded in Q2 2025.
  • Artiva Biotherapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $662000.0 during Q3 2025, with a 5-year trough of $500000.0 in Q2 2023.
  • Its 3-year average for Depreciation & Amortization (CF) is $601200.0, with a median of $608500.0 in 2024.
  • Data for Artiva Biotherapeutics' Depreciation & Amortization (CF) shows a peak YoY increase of 2060.0% (in 2024) and a maximum YoY decrease of 336.7% (in 2024) over the last 5 years.
  • Artiva Biotherapeutics' Depreciation & Amortization (CF) (Quarter) stood at $594000.0 in 2023, then rose by 3.37% to $614000.0 in 2024, then grew by 7.82% to $662000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $662000.0 for Q3 2025, versus $641000.0 for Q2 2025 and $628000.0 for Q1 2025.